Haemonetics Corporation  

(Public, NYSE:HAE)   Watch this stock  
Find more results for HAE
41.14
+1.25 (3.13%)
May 17 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 39.92 - 41.14
52 week 32.69 - 44.44
Open 40.17
Vol / Avg. 596,412.00/349,560.00
Mkt cap 2.12B
P/E 55.39
Div/yield     -
EPS 0.74
Shares 51.64M
Beta 0.42
Inst. own 103%
Jul 29, 2013
Q1 2014 Haemonetics Corporation Earnings Release Add to calendar
May 16, 2013
Haemonetics Investor Day - Webcast
May 1, 2013
Q4 2013 Haemonetics Corporation Earnings Conference Call - Webcast
Apr 29, 2013
Q4 2013 Haemonetics Corporation Earnings Release
Mar 6, 2013
Haemonetics Corporation at Raymond James Institutional Investors Conference
Feb 26, 2013
Haemonetics Corporation at Citi Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2013
Net profit margin 5.03% 4.35%
Operating margin 7.08% 6.33%
EBITD margin - 14.14%
Return on average assets 3.43% 3.27%
Return on average equity 6.51% 5.17%
Employees 2,337 -
Carbon Disclosure Rating - -

Address

400 Wood Road
BRAINTREE, MA 02184-9114
United States - Map
+1-781-8487100 (Phone)
+1-781-8485106 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Haemonetics Corporation is a healthcare company. The Company is engaged developing and manufacturing automated blood component collection devices and surgical blood salvage devices. The Company offer devices and related consumables, information technology software platforms, and consulting services. Its customers are blood and plasma collectors, hospitals and health care providers globally. The Company has four global product families: plasma, blood center, hospital, and software solutions. Its products include equipment devices and the related disposables used with these devices. Disposables include the plasma, blood center and hospital product families. Plasma consists of the disposables used to perform apheresis for the separation of whole blood components. In August 2012, Pall Corporation sold the business assets of its blood collection, filtration and processing product lines to the Company. In May 2013, the Company acquired Hemerus Medical, LLC.

Officers and directors

Brian P. Concannon President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Christopher J. Lindop Chief Financial Officer, Vice President
Age: 54
Bio & Compensation  - Reuters
Peter M. Allen President - Global Plasma
Age: 53
Bio & Compensation  - Reuters
Michael Kelly President, North America
Age: 48
Bio & Compensation  - Reuters
Susan Hanlon Vice President - Finance
Age: 45
Bio & Compensation  - Reuters
Joseph J. Forish Vice President - Human Resources
Age: 59
Bio & Compensation  - Reuters
David D. Helsel Vice President - Global Manufacturing
Age: 49
Bio & Compensation  - Reuters
Sandra Jesse Vice President, Chief Legal Officer
Age: 59
Bio & Compensation  - Reuters
Warren Nighan Vice President - Worldwide Quality & Regulatory Affairs
Age: 43
Bio & Compensation  - Reuters
Jonathan White Vice President - Research & Development
Age: 52
Bio & Compensation  - Reuters